• LAST PRICE
    2.5400
  • TODAY'S CHANGE (%)
    Trending Down-0.2500 (-8.9606%)
  • Bid / Lots
    2.4800/ 1
  • Ask / Lots
    3.7000/ 1
  • Open / Previous Close
    2.7800 / 2.7900
  • Day Range
    Low 2.5100
    High 2.8155
  • 52 Week Range
    Low 2.5100
    High 15.0000
  • Volume
    29,537
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 2.79
TimeVolumeALRN
09:32 ET11082.78
09:37 ET7002.81
09:51 ET4002.78
09:57 ET7502.8054
10:00 ET10502.8155
10:04 ET5002.78
10:06 ET1002.78
10:38 ET3502.81
10:47 ET1022.75
10:49 ET27942.75
11:14 ET1222.7734
11:50 ET1002.75
11:54 ET39992.74
12:17 ET50522.69
12:26 ET2002.69
12:44 ET1002.661
12:46 ET10002.68
01:22 ET23752.59
01:31 ET1252.5401
01:33 ET19502.5417
02:00 ET2252.54
02:36 ET7002.54
03:03 ET1002.54
03:06 ET2902.51
03:30 ET10002.55
03:46 ET1002.53
03:53 ET1002.55
04:00 ET15002.54
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesALRN
Aileron Therapeutics Inc
12.7M
-0.4x
---
United StatesLIXT
Lixte Biotechnology Holdings Inc
12.7M
-1.5x
---
United StatesBPTH
Bio Path Holdings Inc
12.7M
-0.8x
---
United StatesBRTX
BioRestorative Therapies Inc
12.8M
-0.3x
---
United StatesPSTV
Plus Therapeutics Inc
13.1M
-0.4x
---
United StatesBUDZ
Weed Inc
13.1M
-11.6x
---
As of 2022-12-06

Company Information

Aileron Therapeutics, Inc. is a clinical-stage chemoprotection oncology company. The Company is focused on developing medicines to make chemotherapy safer. ALRN-6924, is its MDM2/MDMX dual inhibitor, which is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the chemoprotective agent in clinical development, which focuses on treating patients with p53-mutated cancers. It is developing ALRN-6924 to selectively protect healthy cells in patients with p53-mutated cancers to reduce or eliminate chemotherapy-induced toxicities. It stabilizes peptides by stapling them with hydrocarbon bonds into their natural alpha-helical conformation. Its platform enables it to chemically stabilize and improve the activity of a range of alpha-helical peptides. ALRN-6924 can pause cell division in cells with wild type (WT), p53, including normal bone marrow cells, and ALRN-6924 has no activity against cancer cells with mutations in p53.

Contact Information

Headquarters
285 Summer Street, Unit 101BOSTON, MA, United States 02210
Phone
617-995-0900
Fax
617-995-2410

Executives

Independent Chairman of the Board
Jeffrey Bailey
President, Chief Executive Officer, Chief Financial Officer, Director
Manuel Alves Aivado
Interim Chief Financial Officer
Susan Drexler
Senior Vice President - Research
D. Allen Annis
Vice President - Program Management and Clinical Operations
Christopher Zergebel

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$12.7M
Revenue (TTM)
$0.00
Shares Outstanding
4.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.86
EPS
$-6.52
Book Value
$9.69
P/E Ratio
-0.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.